Medici List crest

ENANTA PHARMACEUTICALS INC

CIK: 11776482 Annual ReportsLatest: 2026-11-18
Revenue: $63,001,000Net Income: -$68,248,000Source 10-K
Disclaimer: AI-assisted summary of SEC Form 10-K filings. Not official company content and not investment, legal, accounting, or tax advice. See full disclaimer here.

10-K / November 18, 2026

Revenue:$63,001,000
Income:-$68,248,000

10-K / November 27, 2024

Revenue:$67,635,000
Income:-$116,045,000

10-K / November 18, 2026

Enanta Pharmaceuticals, Inc.

Overview

  • Biotechnology company focused on small-molecule drug discovery and development, primarily in viral infections and immunological diseases.
  • Develops wholly owned programs in virology and immunology and out-licenses certain products to partners, including AbbVie for HCV protease inhibitors.
  • Core strategy: advance RSV programs, expand immunology portfolio (KIT, STAT6, MRGPRX2), and pursue collaborations or licensing to accelerate development.

Business model and focus

  • In-house discovery capabilities to generate small-molecule drug candidates.
  • Maintains wholly owned virology and immunology pipelines while pursuing collaborations and out-licensing to commercialize selected assets.
  • Relies on third-party manufacturers for production; AbbVie handles manufacturing for glecaprevir under the HCV collaboration.
  • No approved products marketed directly by Enanta; revenue is primarily royalties and milestone payments from partners.

Key product candidates and programs

Virology

  • Zelicapavir (EDP-938): RSV N-protein inhibitor.
  • EDP-323: RSV L-protein inhibitor.
  • EDP-235: SARS-CoV-2 3CL protease inhibitor with potential pan-coronavirus activity; progressed through Phase 2 in COVID-19 settings and subject to collaboration discussions.
  • RSV clinical programs include RESOLVE (high-risk adults) and LOTUS (pediatric); topline RSV data expected in 2027, with LOTUS topline expected in Q1 2027.

Immunology

  • EDP-978 (KIT inhibitor): clinical candidate for chronic spontaneous urticaria (CSU); first-in-human Phase 1 dosed April 2026, with topline data expected Q1 2027.
  • EDP-903 (STAT6 inhibitor): lead preclinical candidate with IND-enabling activities planned; IND filing targeted for 2Q 2027.
  • EPS-5336 (MRGPRX2 inhibitor): preclinical candidate targeting mast cell degranulation and migraine-relevant pathways; IND-enabling activities planned with an IND filing target in Q4 2027.
  • Ongoing preclinical discovery work to expand the immunology portfolio.

Commercialization and partnerships

  • Collaboration with AbbVie for HCV protease inhibitors (glecaprevir and paritaprevir), which are part of AbbVie’s MAVYRET/MAVIRET and related regimens.
  • Enanta has received $330 million in milestone payments under the AbbVie collaboration.
  • Cumulative MAVYRET/MAVIRET royalties to Enanta totaled about $983 million through September 30, 2026.
  • In April 2023, Enanta sold 54.5% of its future MAVYRET/MAVIRET royalties to OMERS for $200 million, capped at 1.42x the cash payment (capped at $284 million). Enanta continues to recognize 100% of the MAVYRET/MAVIRET royalties for accounting purposes and records the related liability reduction over time.
  • Enanta pursues out-licensing, partnerships, and potential acquisitions or in-licenses to advance RSV and immunology programs.

Financial snapshot (selected metrics)

  • Cash and equivalents: $194.5 million as of September 30, 2026.
  • Funding actions:
    • October 2025 underwritten public offering, net proceeds approximately $69.9 million.
    • July 2026 Open Market Sale Agreement with Jefferies for up to $75.0 million of at-the-market equity sales.
  • Revenue model: primarily royalty payments from AbbVie on MAVYRET/MAVIRET and milestone payments.
  • Net income (loss):
    • FY2026: net loss of $68.2 million.
    • FY2025: net loss of $81.9 million.
    • FY2024: net loss of $116.0 million.
  • Research and development expense:
    • FY2026: $88.5 million.
    • FY2025: $106.7 million.
    • FY2024: $131.5 million.

Product development status and timelines (highlights)

  • RSV: RESOLVE dosed in October 2026; RESOLVE and LOTUS topline RSV data expected in 2027; LOTUS topline expected Q1 2027.
  • EDP-978 (KIT): first-in-human Phase 1 dosed April 2026; topline data expected Q1 2027.
  • EDP-903 (STAT6): IND filing targeted for 2Q 2027.
  • EPS-5336 (MRGPRX2): IND-enabling activities ongoing with an IND filing target in Q4 2027.
  • EDP-235 (SARS-CoV-2): progressed through Phase 2 in COVID-19; discussions ongoing for further development.

Corporate, governance and operations

  • Leadership: CEO Jay R. Luly announced intention to retire as President and CEO by February 1, 2027; the board has initiated CEO succession planning. Dr. Luly will remain as a strategic advisor through 2027.
  • Intellectual property: programs are supported by a portfolio of patents and applications; the company manages IP risk as part of its commercialization strategy.
  • Manufacturing and supply: no internal commercial manufacturing capacity; relies on contract manufacturers and partner manufacturing (AbbVie for glecaprevir). The company monitors supply-chain risks, including potential third-party disruptions.

Employees and headquarters

  • 74 full-time employees as of September 30, 2026.
    • 36 hold Ph.D. or M.D. degrees.
    • 16 hold a master’s or other post-graduate degree.
  • Workforce reduction of approximately one-third in September 2026.
  • Headquarters: 4 Kingsbury Avenue, Watertown, Massachusetts 02472.